Brain endothelial cell expression of SPARCL ‐1 is specific to chronic multiple sclerosis lesions and is regulated by inflammatory mediators in vitro

ConclusionsConflicting results of SPARCL‐1's differential expression in CSF of 3 independent cohorts of RRMS and SPMS patients precludes its use as biomarker for disease progression. The expression of SPARCL‐1 by BEC in chronic MS lesions together with its regulation by inflammatory mediators in vitro suggest a role for SPARCL‐1 in MS neuropathology, possibly at the brain vascular level.This article is protected by copyright. All rights reserved.

Source: Neuropathology and Applied Neurobiology - May 24, 2017 Category: Neurology Authors: C Bridel, M J A Koel ‐Simmelink, L Peferoen, C Derada Troletti, S Durieux, R Gorter, E Nutma, P Gami, E Iacobeus, L Brundin, J Kuhle, H Vrenken, J Killestein, S R Piersma, T V Pham, H E De Vries, S Amor, C R Jimenez, C E Teunissen Tags: Original Article Source Type: research